 Professor Tsukasa Kumai, member of the Japans Olympic Committee Medical and Scientific Staff, will lead RepliCels Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC ACCESSWIRE May 3, 2021 RepliCel Life Sciences Inc. OTC PINK:REPCFTSXV:RPFRA:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Tsukasa Kumai, one of Japans leading sports medicine clinicians, has agreed to be RepliCels clinical advisor for the development and commercialization of its tendon regeneration product RCT-01 in Japan. The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its tendon regeneration cell therapy, RCT-01, in Japan under the Act for Safety of Regenerative Medicine ASRM that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan. 